Adenoviral gene therapy

Oncologist

Volumn 7, Issue 1, 2002, Pages 46-59

  Vorburger, Stephan A ^a   Hunt, Kelly K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenoviridiae; Clinical trials; Gene therapy; Genetic vectors; Review literature

Indexed keywords

ADENOVIRUS VECTOR;

ADENOVIRUS; GENE REPLACEMENT THERAPY; GENE THERAPY; IMMUNOTHERAPY; LIFE CYCLE; PRIORITY JOURNAL; REVIEW; SUICIDE GENE THERAPY;

ADENOVIRIDAE; CLINICAL TRIALS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS;

EID: 0036174607     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-1-46     Document Type: Review

References (107)

1. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration
2. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
3. + CTLs in vivo
4. Gene therapy for cancer: What have we done and where are we going?
5. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
6. Biology of E1-deleted adenovirus vectors in nonhuman primate muscle
7. The use of adenoviral vectors for gene therapy and gene transfer in vivo
8. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse
9. Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration
10. Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy
11. Adenovirus-mediated gene therapy in an experimental model of breast cancer metastatic to the brain
12. Adenovirus-mediated gene therapy for experimental spinal cord tumors: Tumoricidal efficacy and functional outcome
13. Adenovirus-mediated gene therapy of experimental gliomas
14. Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo
15. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors
16. The dendritic cell system and its role in immunogenicity
17. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells
18. Reciprocal control of T helper cell and dendritic cell differentiation
19. p53 tumor suppressor gene therapy for cancer
20. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
21. p53 is required for radiation-induced apoptosis in mouse thymocytes
22. p53 status and the efficacy of cancer therapy in vivo
23. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy
24. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53
25. Adenovirus-mediated transfer of caspase-8 augments cell death in gliomas: Implication for gene therapy
26. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain
27. Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirusmediated p53 gene transfer
28. Combination therapy of adenovirus-mediated overexpression of E2F-1 transcription factor and chemotherapy enhances growth suppression in breast cancer cells
29. Ionizing radiation greatly improves gene transfer efficiency in mammalian cells
30. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
31. Killing tumor cells with viruses - A question of specificity
32. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma
33. Productive replication of human adenoviruses in mouse epidermal cells
34. Crisis of adenoviruses in human gene therapy
35. Studies illuminate cause of fatal reaction in gene-therapy trial
36. Adenovirus-mediated gene transfer to liver
37. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
38. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
39. Progress of the smart bomb cancer virus
40. E1B-deleted adenovirus (d11520) gene therapy for patients with primary and secondary liver tumors
41. Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53
42. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
43. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors
44. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene
45. Construction of adenovirus vectors through Cre-lox recombination
46. Expanded-capacity adenoviral vectors - The helper-dependent vectors
47. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted
48. Administration of helperdependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
49. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector
50. High doses of a helperdependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity
51. Novel tools for production and purification of recombinant adenoassociated virus vectors
52. Subcellular compartmentalization of adeno-associated virus type 2 assembly
53. Recombinant adenoassociated virus purification using novel methods improves infectious titer and yield
54. Production of viral vectors for gene therapy applications
55. A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome
56. Adenoviral/retroviral vector chimeras: A novel strategy to achieve high-efficiency stable transduction in vivo
57. Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines
58. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5
59. Considerations and challenges for the achievement of targeted gene delivery
60. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment
61. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia
62. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types
63. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies
64. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins
65. Adenovirus as a gene therapy vector for hematopoietic cells
66. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae
67. Addition of a short peptide ligand to the adenovirus fiber protein
68. A helper-independent adenovirus vector with E1, E3, and fiber deleted: Structure and infectivity of fiberless particles
69. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells
70. Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells
71. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptorindependent cell entry mechanism
72. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector
73. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches
74. Polycations and cationic lipids enhance adenovirus transduction and transgene expression in tumor cells
75. Recombinant adenoviral vector-lipofectAMINE complex for gene transduction into human T lymphocytes
76. Use of protamine to augment adenovirus-mediated cancer gene therapy
77. Strategies to adapt adenoviral vectors for targeted delivery
78. Targeting adenovirus
79. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
80. Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy
81. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines
82. Ionizing radiation activates transcription of the EGR1 gene via CArG elements
83. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells
84. Enhancement of radiotherapy by hyperthermia-regulated gene therapy
85. Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo
86. Chromatin-modifying and -remodeling complexes
87. Coactivator and corepressor complexes in nuclear receptor function
88. Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis
89. Human gene marker/therapy clinical protocols
90. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection
91. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versusleukemia
92. Herpesvirus-mediated systemic delivery of nerve growth factor
93. Multi-modal combination gene therapy for malignant glioma using replication-defective HSV vectors
94. Engineering herpes simplex virus vectors for CNS applications
95. Herpes simplex virus vector-mediated expression of Bc-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo
96. Production and purification of recombinant adeno-associated virus
97. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses
98. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus
99. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy
100. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization
101. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus
102. Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer
103. Efficient lentiviral transduction of liver requires cell cycling in vivo
104. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver
105. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
106. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector